1
|
Mhlanga J, Alazraki A, Cho SY, Lai H, Nadel H, Pandit-Taskar N, Qi J, Rajderkar D, Voss S, Watal P, McCarten K. Imaging recommendations in pediatric lymphoma: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. Pediatr Blood Cancer 2023; 70 Suppl 4:e29968. [PMID: 36114654 PMCID: PMC10641880 DOI: 10.1002/pbc.29968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2022] [Accepted: 08/16/2022] [Indexed: 11/08/2022]
Abstract
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are both malignancies originating in the lymphatic system and both affect children, but many features differ considerably, impacting workup and management. This paper provides consensus-based imaging recommendations for evaluation of patients with HL and NHL at diagnosis and response assessment for both interim and end of therapy (follow-up).
Collapse
Affiliation(s)
- Joyce Mhlanga
- Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, Saint Louis, Missouri, USA
| | - Adina Alazraki
- Departments of Pediatrics and Radiology, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia, USA
| | - Steve Y Cho
- Department of Radiology, Nuclear Medicine and Molecular Imaging Section, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Hollie Lai
- Department of Radiology, Children's Health of Orange County, Orange, California, USA
| | - Helen Nadel
- Department of Pediatric Radiology, Lucile Packard Children's Hospital at Stanford, Stanford University School of Medicine, Stanford, California, USA
| | - Neeta Pandit-Taskar
- Department of Radiology, Molecular imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
- Department of Radiology, Weill Cornell Medical College, New York City, New York, USA
| | - Jing Qi
- Department of Radiology, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, Wisconsin, USA
| | - Dhanashree Rajderkar
- Department of Radiology, Division of Pediatric Radiology, College of Medicine, University of Florida, Gainesville, Florida, USA
| | - Stephan Voss
- Harvard Medical School, Department of Radiology, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Pankaj Watal
- University of Central Florida College of Medicine, Nemours Children's Hospital, Orlando, Florida, USA
| | - Kathleen McCarten
- Diagnostic Imaging and Pediatrics, Imaging and Radiation Oncology Core, Lincoln, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA
| |
Collapse
|
2
|
Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplant Cell Ther 2022; 28:610-617. [DOI: 10.1016/j.jtct.2022.06.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 05/10/2022] [Accepted: 06/16/2022] [Indexed: 11/23/2022]
|
3
|
Hatta S, Fukuhara S, Fujino T, Saito Y, Ito Y, Makita S, Munakata W, Suzuki T, Maruyama D, Kusumoto M, Izutsu K. The role of surveillance computed tomography in patients with follicular lymphoma. Ther Adv Hematol 2022; 13:20406207221095963. [PMID: 35585967 PMCID: PMC9109489 DOI: 10.1177/20406207221095963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 04/04/2022] [Indexed: 11/15/2022] Open
Abstract
Introduction Surveillance computed tomography (CT) is performed during the follow-up of patients with lymphoma who have completed initial therapy. However, studies on the clinical benefit of surveillance CT for patients with incurable subtypes, such as follicular lymphoma (FL), are limited. This study aimed to evaluate the value of surveillance CT for patients with FL after achieving the first complete response (CR) or CR unconfirmed in the rituximab era. Methods We retrospectively reviewed the medical records of patients with FL who achieved CR with first-line treatment between 2000 and 2016 at our institution. In patients who experienced first relapse, we examined the patient's clinical characteristics at the time of relapse, subsequent therapies, and post-relapse survival, based on the method of relapse detection. Results Of the 248 patients who achieved CR after initial therapy, 109 had a relapse, with a median follow-up of 11 years; 100 were enrolled into this study. Relapse was detected by surveillance CT in 61 patients (surveillance CT group) and by means other than surveillance CT, such as the presence of patient-reported symptoms, physical findings, and blood work-up abnormalities (non-surveillance CT group), in 39 patients. There was no significant difference in the patients' characteristics at the time of relapse between the two groups, except for a higher incidence of extranodal involvement in the non-surveillance CT group. The method of relapse detection did not affect therapeutic selection after relapse and post-relapse survival. In this study, 86.8% of the 38 patients who relapsed with only deep lesions, such as mesenteric or retroperitoneal lymph nodes, had surveillance CT-detected relapse. Conclusion Surveillance CT did not show any clinical benefit for patients with FL in CR; however, it might lead to early detection of relapse in cases of deep lesions that cannot be identified without imaging.
Collapse
Affiliation(s)
- Shunsuke Hatta
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - Suguru Fukuhara
- Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
| | - Takahiro Fujino
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - Yo Saito
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - Yuta Ito
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - Shinichi Makita
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - Wataru Munakata
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - Tatsuya Suzuki
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - Dai Maruyama
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - Masahiko Kusumoto
- Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan
| | - Koji Izutsu
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
4
|
PET imaging of lymphomas. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00047-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
5
|
Al Tabaa Y, Bailly C, Kanoun S. FDG-PET/CT in Lymphoma: Where Do We Go Now? Cancers (Basel) 2021; 13:cancers13205222. [PMID: 34680370 PMCID: PMC8533807 DOI: 10.3390/cancers13205222] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 10/11/2021] [Accepted: 10/15/2021] [Indexed: 01/06/2023] Open
Abstract
18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is an essential part of the management of patients with lymphoma at staging and response evaluation. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma but also points out the potential place of innovative PET/CT metrics or new radiopharmaceuticals in the future.
Collapse
Affiliation(s)
- Yassine Al Tabaa
- Scintidoc Nuclear Medicine Center, 25 rue de Clémentville, 34070 Montpellier, France
- Correspondence:
| | - Clement Bailly
- CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, 44093 Nantes, France;
- Nuclear Medicine Department, University Hospital, 44093 Nantes, France
| | - Salim Kanoun
- Nuclear Medicine Department, Institute Claudius Regaud, 31100 Toulouse, France;
- Cancer Research Center of Toulouse (CRCT), Team 9, INSERM UMR 1037, 31400 Toulouse, France
| |
Collapse
|
6
|
El-Galaly TC, Øvlisen AK, Cheah CY. Routine imaging for disease surveillance in follicular lymphoma-To comfort the patients or their doctors? Cancer 2021; 127:3298-3301. [PMID: 34157785 DOI: 10.1002/cncr.33659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 04/07/2021] [Accepted: 05/01/2021] [Indexed: 11/08/2022]
Affiliation(s)
- Tarec Christoffer El-Galaly
- Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Andreas Kiesbye Øvlisen
- Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Chan Yoon Cheah
- Department of Hematology, Sir Gairdner Hospital, Perth, Western Australia, Australia.,Medical School, University of Western Australia, Perth, Western Australia, Australia
| |
Collapse
|
7
|
Fukuta T, Nishimura N, Shirouchi Y, Inoue N, Uryu H, Kusano Y, Mishima Y, Yokoyama M, Tsuyama N, Takeuchi K, Terui Y. Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study. Int J Hematol 2020; 111:567-573. [PMID: 31939076 DOI: 10.1007/s12185-020-02819-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Revised: 01/02/2020] [Accepted: 01/07/2020] [Indexed: 11/30/2022]
Abstract
The aim of this study was to evaluate the value of scheduled imaging for patients who achieved first complete remission after CHOP-like chemotherapy plus rituximab. In this retrospective cohort study, we included 759 patients newly diagnosed with de novo diffuse large B-cell lymphoma (DLBCL) at the Cancer Institute, Japanese Foundation for Cancer Research. Relapsed patients were divided into two groups based on method of diagnosis: clinical symptoms (symptom group, n = 57) or scheduled imaging (imaging group, n = 27). Our primary goal was to compare overall survival and relapse-free survival between the two groups. No significant difference in outcomes was found between the symptom and imaging groups. Median overall survival [7.5 years; 95% confidence interval (CI) 4.0-9.7 vs. 9.1 years; 95% CI 2.7 to not reached; P = 0.747), and median relapse-free survival (1.8 years; 95% CI 1.4-2.5 vs. 2.4 years; 95% CI 1.2-4.4; P = 0.108). Surveillance imaging in patients with DLBCL who achieved first complete remission did not demonstrate an advantage in terms of overall survival or relapse-free survival.
Collapse
Affiliation(s)
- Takanori Fukuta
- Department of Hematology and Oncology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan.
| | - Noriko Nishimura
- Department of Hematology and Oncology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan
| | - Yuko Shirouchi
- Department of Hematology and Oncology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan
| | - Norihito Inoue
- Department of Hematology and Oncology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan
| | - Hideki Uryu
- Department of Hematology and Oncology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan
| | - Yoshiharu Kusano
- Department of Hematology and Oncology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan
| | - Yuko Mishima
- Department of Hematology and Oncology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan
| | - Masahiro Yokoyama
- Department of Hematology and Oncology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan
| | - Naoko Tsuyama
- Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Kengo Takeuchi
- Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.,Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Yasuhito Terui
- Department of Hematology and Oncology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan
| |
Collapse
|
8
|
Kallam A, Adusumalli J, Armitage JO. Surveillance in Patients With Diffuse Large B Cell Lymphoma. Mayo Clin Proc 2020; 95:157-163. [PMID: 31902411 DOI: 10.1016/j.mayocp.2019.05.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Revised: 05/03/2019] [Accepted: 05/14/2019] [Indexed: 01/28/2023]
Abstract
With improvement in the cure rates for diffuse large B cell lymphoma, the question of surveillance imaging in patients who achieve complete remission after the initial therapy has become relevant. Some of the clinical practice guidelines recommend surveillance scanning. However, several studies have reported no benefit in overall survival with scans. Moreover, studies have highlighted an increased risk for developing secondary malignancies because of exposure to ionizing radiation from the scans. Different international societies have contrasting guidelines for the role of surveillance computerized tomography scans in patients who achieve complete remission after first-line therapy. Any benefit of surveillance imaging must be balanced by the costs, risk of radiation exposure, and lack of survival benefit. The PubMed platform was searched using relevant keywords for English-language articles with no date restrictions. Search terms were cross-referenced with review articles, and additional articles were identified by manually searching reference lists. Results were reviewed by the authors and selected for inclusion based on relevance. We present a review of this current data available for surveillance imaging in patients with diffuse large B cell lymphoma.
Collapse
Affiliation(s)
- Avyakta Kallam
- Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha.
| | | | - James O Armitage
- Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha
| |
Collapse
|
9
|
JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-overview. Int J Hematol 2019; 110:3-10. [PMID: 31152416 DOI: 10.1007/s12185-019-02676-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 05/07/2019] [Indexed: 12/12/2022]
|
10
|
Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA. Best Pract Res Clin Haematol 2018; 31:285-292. [PMID: 30213398 DOI: 10.1016/j.beha.2018.07.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Revised: 06/27/2018] [Accepted: 07/02/2018] [Indexed: 12/12/2022]
Abstract
Recent guidelines have de-emphasized the role of routine surveillance computed tomography (CT) scans for diffuse large B-cell lymphoma (DLBCL) patients who achieve a complete response to front-line therapy. This shift in practice recommendations was prompted by retrospective studies that failed to demonstrate clear clinical utility for surveillance CT in unselected DLBCL patients. Controversy remains, however, over the role of routine surveillance CT in the highest risk patients for treatment failure who would remain candidates for aggressive salvage therapies. Novel high-throughput sequencing methods can non-invasively monitor tumor-specific DNA in the blood and offers clear advantages designed to overcome fundamental limitations of CT scans. This review will discuss the current controversies surrounding monitoring clinical outcomes in aggressive B-cell lymphomas, with a specific emphasis on DLBCL. Fundamental limitations of imaging scans will be addressed and the potential of monitoring circulating tumor DNA as an adjunct or replacement for CT scans will be discussed.
Collapse
|
11
|
Hiniker SM, Hoppe RT. Post-treatment surveillance imaging in lymphoma. Semin Oncol 2018; 44:310-322. [PMID: 29580433 DOI: 10.1053/j.seminoncol.2018.01.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Revised: 01/31/2018] [Accepted: 01/31/2018] [Indexed: 01/17/2023]
Abstract
Appropriate post-treatment management of patients with lymphoma has been controversial, with imaging frequently performed as post-treatment surveillance. The goal of post-treatment imaging is to identify relapse prior to clinical symptoms, when the burden of disease is lower and the possibility of effective salvage therapy and cure are greater. However, little data exist to support the performance of surveillance imaging after completion of treatment, with the vast majority of studies suggesting there is no clinical benefit to surveillance imaging in asymptomatic patients. Ongoing efforts seek to identify a subset of patients with a higher risk of relapse that might benefit from surveillance imaging, though financial and other costs associated with imaging are non-negligible and must be considered. Here we summarize the current data regarding post-treatment surveillance imaging in lymphoma.
Collapse
Affiliation(s)
- Susan M Hiniker
- Department of Radiation Oncology, Stanford University, Stanford, CA.
| | - Richard T Hoppe
- Department of Radiation Oncology, Stanford University, Stanford, CA
| |
Collapse
|
12
|
Buedts L, Vandenberghe P. Circulating cell-free DNA in hematological malignancies. Haematologica 2018; 101:997-9. [PMID: 27582567 DOI: 10.3324/haematol.2015.131128] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Affiliation(s)
- Lieselot Buedts
- Center for Human Genetics, University Hospitals KU Leuven, Belgium
| | | |
Collapse
|
13
|
Kang KW, Lee SR, Kim DS, Yu ES, Sung HJ, Kim SJ, Choi CW, Park Y, Kim BS. Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma. PLoS One 2018; 13:e0192656. [PMID: 29444176 PMCID: PMC5812643 DOI: 10.1371/journal.pone.0192656] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2017] [Accepted: 01/26/2018] [Indexed: 11/23/2022] Open
Abstract
Surveillance computed tomography (CT) is usual practice for patients with aggressive non-Hodgkin lymphoma (aNHL) in complete remission (CR). However, evidence to support this strategy is lacking. We retrospectively analyzed our institutional lymphoma registry, including patients with lymphoma consecutively enrolled from June 1995 to October 2016. Of 1,385 patients with aNHL, 664 achieved CR and were followed up with or without surveillance CT. Surveillance CT was performed for 609 patients every 3 or 6 months for the first 2 years, then every 6 or 12 months thereafter. Relapse was detected in 171 patients, of whom 152 underwent surveillance CT during follow-up. Of these 152 patients, asymptomatic relapse was detected in 67 (44%) using surveillance CT, and symptomatic relapse outside the surveillance interval was detected in the remaining 85 (56%). Detection of asymptomatic relapse using surveillance CT did not improve the overall or post-relapse survival in patients with relapsed aNHL. Surveillance CT interval (3 or 6 months) did not affect survival. No subgroups were identified that favored the use of surveillance CT to detect relapse. The results of this study suggest that routine surveillance CT in patients with aNHL to detect asymptomatic relapse might have a limited role in improving survival. CT is recommended when a relapse is clinically suspected.
Collapse
Affiliation(s)
- Ka-Won Kang
- Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
| | - Se Ryeon Lee
- Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
| | - Dae Sik Kim
- Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
| | - Eun Sang Yu
- Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
| | - Hwa Jung Sung
- Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
| | - Seok Jin Kim
- Division of Hematology-Oncology, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - Chul Won Choi
- Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
| | - Yong Park
- Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
| | - Byung Soo Kim
- Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
| |
Collapse
|
14
|
Karls S, Shah H, Jacene H. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. Semin Nucl Med 2018; 48:37-49. [DOI: 10.1053/j.semnuclmed.2017.09.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
15
|
Vollmer K, Mamot C. [Not Available]. PRAXIS 2018; 107:31-34. [PMID: 29295676 DOI: 10.1024/1661-8157/a002861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Zusammenfassung. Aufgrund der verbesserten therapeutischen Möglichkeiten kann mittels Immunochemotherapie eine beträchtliche Anzahl der Patienten mit diffusem grosszelligem B-Zell-Lymphom geheilt werden. In diesem Zusammenhang stellt sich die Frage nach der korrekten Nachsorge zur Früherkennung eines Rezidivs. Die im Rahmen dieses Mini-Reviews dargelegte Evidenz zeigt, dass weder mit Routinebildgebungen noch mit entsprechender routinemässiger Labordiagnostik die Früherkennung von asymptomatischen Rezidiven gelingt. Auch kann die Früherkennung des Rezidivs die Prognose der Patienten nicht verbessern. Das Rezidiv wird meist klinisch diagnostiziert mit neuen Symptomen oder Befunden. Die Nachsorge, die klinisch orientiert durchgeführt werden sollte, soll in erster Linie der Erkennung von Spätfolgen und zur Wiedereingliederung in Beruf und Gesellschaft dienen.
Collapse
|
16
|
El-Galaly TC, Cheah CY. Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission. Leuk Lymphoma 2017; 59:775-777. [PMID: 28828884 DOI: 10.1080/10428194.2017.1365863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Tarec C El-Galaly
- a Department of Haematology , Aalborg University Hospital , Aalborg , Denmark
| | - Chan Yoon Cheah
- b Department of Haematology , Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine WA , Nedlands , Australia.,c Medical School , University of Western Australia , Crawley , Australia
| |
Collapse
|
17
|
Kwok M, Wu SP, Mo C, Summers T, Roschewski M. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas. Curr Treat Options Oncol 2017; 17:47. [PMID: 27461036 DOI: 10.1007/s11864-016-0425-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
OPINION STATEMENT The goal of therapy for aggressive B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) is to achieve cure. Combination chemotherapy with rituximab cures most patients, but those with recurrent disease have a poor prognosis. Medical imaging scans such as computed tomography (CT) and positron emission tomography (PET) are the principal methods to assess response and monitor for disease relapse after therapy but are fundamentally limited by risks of radiation, cost, and a lack of tumor specificity. Novel sequencing-based DNA monitoring methods are capable of quantifying small amounts of circulating tumor DNA (ctDNA) before, during, and after therapy for mature B-cell lymphomas. Detection of ctDNA encoding clonal rearranged variable-diversity-joining (VDJ) receptor gene sequences has demonstrated improved analytical sensitivity and enhanced tumor specificity compared to imaging scans in DLBCL, offering broad clinical applicability across a range of aggressive B-cell lymphomas. Molecular monitoring of ctDNA has vaulted into the spotlight as a promising non-invasive tool with immediate clinical impact on monitoring for recurrence after therapy prior to clinical symptoms. As these clinical observations are validated, ctDNA monitoring needs to be investigated as a tool for response-adapted therapy and as a marker of minimal residual disease upon completion of therapy in aggressive B-cell lymphomas. Molecular monitoring of ctDNA holds tremendous promise that may ultimately transform our ability to monitor disease in aggressive B-cell lymphomas.
Collapse
MESH Headings
- Biomarkers, Tumor
- DNA, Neoplasm/blood
- DNA, Neoplasm/genetics
- Diagnostic Imaging
- Disease Progression
- Genetic Testing/methods
- Genetic Testing/standards
- Genomics/methods
- Genomics/standards
- High-Throughput Nucleotide Sequencing
- Humans
- Lymphoma, B-Cell/diagnosis
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/therapy
- Lymphoma, Large B-Cell, Diffuse/diagnosis
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/therapy
- Neoplasm, Residual/diagnosis
- Neoplasm, Residual/genetics
- Treatment Outcome
Collapse
Affiliation(s)
- Mary Kwok
- Hematology-Oncology Department, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, 4954 N. Palmer Road, Bethesda, MD, 20889, USA
| | - S Peter Wu
- Internal Medicine Department, Perlmutter Cancer Center, New York University Langone Medical Center, 560 E 34th Street, New York, NY, 10016, USA
| | - Clifton Mo
- Hematology-Oncology Department, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, 4954 N. Palmer Road, Bethesda, MD, 20889, USA
| | - Thomas Summers
- Pathology Department, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20895, USA
| | - Mark Roschewski
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bldg 10, Room 4N/115, Bethesda, MD, 20892, USA.
| |
Collapse
|
18
|
Abstract
OPINION STATEMENT Advancements in the treatment of lymphoma over the last few decades have allowed more patients to achieve a remission after the completion of therapy. Due to the improvement in response rates, methods to detect recurrence early and accurately during follow-up, especially in patients with potential curable aggressive lymphomas, are a key. Observation has always involved close clinical follow-up with the use of physical exams and routine labs, but rapid changes in technology have allowed CT scans, PET scans, and MRIs to become an integral part of managing patients with lymphoma. While the utility of scans in initial staging and immediately after completion of therapy is well established, the use of these imaging modalities for monitoring recurrence in lymphoma patients is still controversial. Patient advocacy groups and other regulatory committees have questioned the frequency and in some cases even the need for these tests in patients without evidence of active disease given the concern for radiation-associated health risks. Additionally, the extent to which this form of testing impacts the psyche of our patients is not completely known. Given the numerous questions raised about the benefits, safety, and cost-effectiveness of CT imaging, firm guidelines are needed at this time in standard practice and within our clinical trials to limit the use of surveillance imaging. Such efforts are expected to improve the utility of these scans in asymptomatic patients, reduce healthcare costs, and reduce patient exposure to radiation.
Collapse
Affiliation(s)
- Tycel Phillips
- Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.
| | - Jessica Mercer
- Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA
| |
Collapse
|
19
|
Cederleuf H, Hjort Jakobsen L, Ellin F, de Nully Brown P, Stauffer Larsen T, Bøgsted M, Relander T, Jerkeman M, El-Galaly TC. Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. Leuk Lymphoma 2017; 58:2815-2823. [DOI: 10.1080/10428194.2017.1300888] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Henrik Cederleuf
- Department of Clinical Sciences, Oncology and Pathology, Lund University, Lund, Sweden
| | - Lasse Hjort Jakobsen
- Department of Haematology, Aalborg University Hospital, Aalborg, Denmark
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Fredrik Ellin
- Department of Clinical Sciences, Oncology and Pathology, Lund University, Lund, Sweden
- Department of Internal Medicine, Kalmar County Hospital, Kalmar, Sweden
| | - Peter de Nully Brown
- Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | | | - Martin Bøgsted
- Department of Haematology, Aalborg University Hospital, Aalborg, Denmark
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Thomas Relander
- Department of Clinical Sciences, Oncology and Pathology, Lund University, Lund, Sweden
| | - Mats Jerkeman
- Department of Clinical Sciences, Oncology and Pathology, Lund University, Lund, Sweden
| | - Tarec Christoffer El-Galaly
- Department of Haematology, Aalborg University Hospital, Aalborg, Denmark
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| |
Collapse
|
20
|
Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2016; 16:672-678. [DOI: 10.1016/j.clml.2016.08.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Revised: 08/13/2016] [Accepted: 08/18/2016] [Indexed: 01/26/2023]
|
21
|
Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma. Hematol Oncol Clin North Am 2016; 30:1215-1228. [DOI: 10.1016/j.hoc.2016.07.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
22
|
Sussman J, Varela N, Cheung M, Hicks L, Kraftcheck D, Mandel J, Fraser G, Jimenez-Juan L, Boudreau A, Sajkowski S, McQuillan R. Follow-up care for survivors of lymphoma who have received curative-intent treatment. Curr Oncol 2016; 23:e499-e513. [PMID: 27803611 PMCID: PMC5081023 DOI: 10.3747/co.23.3265] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
OBJECTIVE This evidence summary set out to assess the available evidence about the follow-up of asymptomatic survivors of lymphoma who have received curative-intent treatment. METHODS The medline and embase databases and the Cochrane Database of Systematic Reviews were searched for evidence published between 2000 and August 2015 relating to lymphoma survivorship follow-up. The evidence summary was developed by a Working Group at the request of the Cancer Care Ontario Survivorship and Cancer Imaging programs because of the absence of evidence-based practice documents in Ontario for the follow-up and surveillance of asymptomatic patients with lymphoma in complete remission. RESULTS Eleven retrospective studies met the inclusion criteria. The proportion of relapses initially detected by clinical manifestations ranged from 13% to 78%; for relapses initially detected by imaging, the proportion ranged from 8% to 46%. Median time for relapse detection ranged from 8.6 to 19 months for patients initially suspected because of imaging and from 8.6 to 33 months for those initially suspected because of clinical manifestations. Only one study reported significantly earlier relapse detection for patients initially suspected because of clinical manifestations (mean: 4.5 months vs. 6.0 months, p = 0.042). No benefit in terms of overall survival was observed for patients depending on whether their relapse was initially detected because of clinical manifestations or surveillance imaging. SUMMARY Findings in the present study support the importance of improving awareness on the part of survivors and clinicians about the symptoms that might be associated with recurrence. The evidence does not support routine imaging for improving outcomes in this patient population.
Collapse
Affiliation(s)
- J. Sussman
- Division of Radiation Oncology, Juravinski Cancer Centre, Hamilton
| | - N.P. Varela
- Cancer Care Ontario, Program in Evidence-Based Care, McMaster University, Hamilton
| | - M. Cheung
- Odette Cancer Centre, Sunny-brook Health Sciences Centre, Toronto
| | - L. Hicks
- Division of Hematology/Oncology, St. Michael’s Hospital, Toronto
| | - D. Kraftcheck
- Provincial Primary Care and Cancer Network, Hamilton Niagara Haldimand Brant, Grimsby
| | - J. Mandel
- Department of Diagnostic Imaging and Nuclear Medicine, Oakville Trafalgar Memorial Hospital, Oakville
| | - G. Fraser
- Division of Malignant Hematology, Juravinski Cancer Centre, Hamilton
| | | | - A. Boudreau
- Sunnybrook Health Sciences Centre, Toronto and
| | - S. Sajkowski
- Cancer Care Ontario Patient and Family Advisor, Toronto, ON
| | - R. McQuillan
- Cancer Care Ontario Patient and Family Advisor, Toronto, ON
| |
Collapse
|
23
|
Graña L, Calzado A, Hernández P, Rodríguez R. Role of computed tomography on large B-cell non-Hodgkin's lymphoma follow-up and the risk of radiation-induced neoplasm: A retrospective cohort study. Eur J Radiol 2016; 85:673-9. [PMID: 26860683 DOI: 10.1016/j.ejrad.2015.12.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Revised: 12/28/2015] [Accepted: 12/31/2015] [Indexed: 11/29/2022]
Abstract
INTRODUCTION To evaluate the role of surveillance computed tomography (CT) in detection of tumor relapse after complete remission for large-cell lymphoma and to estimate the cancer risk related to those examinations. MATERIALS AND METHODS We retrospectively identified the cases of large-cell lymphoma diagnosed at our institution during a fifteen years period. We extracted from charts the information needed. Agreement between clinical and radiological evaluation for relapse detection was determined with index kappa and McNemar tests. We analysed the surveillance CT examinations performed to the patients in complete remission with no recurrence during the follow-up period and we estimated the life attributable risk (LAR) of radiation-induced cancer above base line using the approach of the Biological Effects of Ionizing Radiation (BEIR) VII. RESULTS 184 patients with biopsy confirmed large-cell lymphoma were included. Complete remission was attained in 125 patients. After a median follow-up of 93.73 months, 97 of them remain in remission. Relapse was confirmed in 28 patients; only 3 of them were asymptomatic. Kappa and McNemar analyses revealed good agreement for diagnosis of recurrence and significant difference for exclusion of relapse. Patients in remission received a median of 6 surveillance CT examinations. Fifty-seven patients had total cumulative doses greater than 100mSv. The mean increase in estimated radiation-induced cancer risk was 0.5%. CONCLUSION Our results suggest that periodic CT examinations have a limited role in detecting relapse in large-cell lymphoma as the clinical surveillance dictates the patient management.
Collapse
Affiliation(s)
- Lucía Graña
- Department of Radiology, Hospital Clínico San Carlos, Profesor Martín Lagos s/n, 28040 Madrid, Spain.
| | - Alfonso Calzado
- Medical Physics Group, Department of Radiology, Complutense University, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.
| | - Paula Hernández
- Department of Radiology, Hospital Clínico San Carlos, Profesor Martín Lagos s/n, 28040 Madrid, Spain.
| | - Ricardo Rodríguez
- Department of Radiology, Hospital Clínico San Carlos, Profesor Martín Lagos s/n, 28040 Madrid, Spain.
| |
Collapse
|
24
|
El-Galaly TC, Jakobsen LH, Hutchings M, de Nully Brown P, Nilsson-Ehle H, Székely E, Mylam KJ, Hjalmar V, Johnsen HE, Bøgsted M, Jerkeman M. Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish–Swedish Population-Based Study. J Clin Oncol 2015; 33:3993-8. [DOI: 10.1200/jco.2015.62.0229] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Routine imaging for diffuse large B-cell lymphoma (DLBCL) in first complete remission (CR) is controversial and plays a limited role in detecting relapse. This population-based study compared the survival of Danish and Swedish patients with DLBCL for whom traditions for routine imaging have been different. Patients and Methods Patients from the Danish and Swedish lymphoma registries were included according to the following criteria: newly diagnosed DLBCL from 2007 to 2012, age 18 to 65 years, and CR after R-CHOP/CHOEP. Follow-up for Swedish patients included symptom assessment, clinical examinations, and blood tests at 3- to 4-month intervals for 2 years, with longer intervals later in follow-up. Imaging was only recommended when relapse was clinically suspected. Follow-up for Danish patients was similar but included routine imaging (usually computed tomography every 6 months for 2 years). Results Danish (n = 525) and Swedish (n = 696) patients with DLBCL had comparable baseline characteristics. Cumulative 2-year progression rate after CR was 6% (95% CI, 4 to 9) for International Prognostic Index (IPI) ≤ 2 versus 21% (95% CI, 13 to 28) for IPI > 2. Age > 60 years (hazard ratio [HR], 2.3; 95% CI, 1.6 to 3.4), elevated lactate dehydrogenase (HR, 2.3; 95% CI, 1.4 to 3.8), B symptoms (HR, 1.7; 95% CI, 1.1 to 2.5), and Eastern Cooperative Oncology Group performance status ≥ 2 (HR, 1.8; 95% CI, 1.0 to 3.0) were associated with worse post-CR survival. Imaging-based follow-up strategy had no impact on survival, neither for all patients nor for IPI-specific subgroups. Conclusion DLBCL relapse after first CR is infrequent, and the widespread use of routine imaging in Denmark did not translate into better survival. This favors follow-up without routine imaging and, more generally, a shift of focus from relapse detection to improved survivorship.
Collapse
Affiliation(s)
- Tarec Christoffer El-Galaly
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| | - Lasse Hjort Jakobsen
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| | - Martin Hutchings
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| | - Peter de Nully Brown
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| | - Herman Nilsson-Ehle
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| | - Elisabeth Székely
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| | - Karen Juul Mylam
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| | - Viktoria Hjalmar
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| | - Hans Erik Johnsen
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| | - Martin Bøgsted
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| | - Mats Jerkeman
- Tarec Christoffer El-Galaly, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University Hospital; Tarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Hans Erik Johnsen, and Martin Bøgsted, Aalborg University, Aalborg; Martin Hutchings and Peter de Nully Brown, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Karen Juul Mylam, Odense University Hospital, Odense, Denmark; Herman Nilsson-Ehle, Sahlgrenska University Hospital, Gothenburg; Elisabeth Székely and Mats Jerkeman, Lund University Hospital
| |
Collapse
|
25
|
Importance of Histologic Verification of Positive Positron Emission Tomography/Computed Tomography Findings in the Follow-Up of Patients With Malignant Lymphoma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2015; 15:753-60. [DOI: 10.1016/j.clml.2015.07.636] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/25/2015] [Revised: 07/08/2015] [Accepted: 07/28/2015] [Indexed: 12/26/2022]
|
26
|
Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse. Case Rep Med 2015; 2015:137682. [PMID: 26457084 PMCID: PMC4592711 DOI: 10.1155/2015/137682] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2015] [Accepted: 09/10/2015] [Indexed: 11/17/2022] Open
Abstract
Herein, we aimed to report a diffuse large B cell lymphoma (DLBCL) case that had extensive cutaneous relapse with no skin involvement previously. A 59-year-old man presented to hospital in April 2014 with fatigue, anorexia, fever, and anemia. Cervical lymph node biopsy revealed CD20+, BCL2+, MUM1+, BCL6+ high grade B lymphoproliferative neoplasm. After FISH investigation, he was diagnosed as DLBCL. He was given 7 cycles of R-CHOP and achieved remission. However, in November 2014, he had emerging skin lesions that cover nearly all of his body. A control PET-CT revealed diffuse cutaneous involvement. CD20+, BCL2+, MUM1+, BCL6+ high grade B cell lymphoma infiltration was detected with skin biopsy. He was diagnosed as relapse lymphoma, so 2 cycles of R-DHAP were given. There was no treatment response; therefore, R-ICE regimen was started. The patient had achieved second complete remission and his skin lesions were completely regressed. The involvement of skin with CD20+ cells after 7 cycles of rituximab therapy favors that there is a rituximab resistant disease which tends to involve the skin. To conclude, DLBCL may relapse extensively with cutaneous involvement and the best treatment option in these patients is salvage chemotherapy followed by autologous peripheral blood stem cell transplantation.
Collapse
|
27
|
FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. Clin Transl Imaging 2015. [DOI: 10.1007/s40336-015-0134-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
28
|
Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys 2015; 92:99-106. [PMID: 25863757 DOI: 10.1016/j.ijrobp.2015.01.039] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 01/19/2015] [Accepted: 01/27/2015] [Indexed: 11/30/2022]
Abstract
BACKGROUND The role of surveillance studies in limited-stage diffuse large B-cell lymphoma (DLBCL) in the rituximab era has not been well defined. We sought to evaluate the use of imaging (computed tomography [CT] and positron emission tomography [PET]-CT) scans and lactate dehydrogenase (LDH) in surveillance of patients with stage I to II DLBCL. METHODS A retrospective analysis was performed of patients who received definitive treatment between 2000 and 2013. RESULTS One hundred sixty-two consecutive patients with stage I to II DLBCL were treated with chemotherapy +/- rituximab, radiation, or combined modality therapy. The 5-year rates of overall survival (OS) and freedom from progression (FFP) were 81.2% and 80.8%, respectively. Of the 162 patients, 124 (77%) were followed up with at least 1 surveillance PET scan beyond end-of-treatment scans; of those, 94 of 124 (76%) achieved a complete metabolic response on PET scan after completion of chemotherapy, and this was associated with superior FFP (P=.01, HR=0.3) and OS (P=.01, HR 0.3). Eighteen patients experienced relapse after initial response to therapy. Nine relapses were initially suspected by surveillance imaging studies (8 PET, 1 CT), and 9 were suspected clinically (5 by patient-reported symptoms and 4 by symptoms and physical examination). No relapses were detected by surveillance LDH. The median duration from initiation of treatment to relapse was 14.3 months among patients with relapses suspected by imaging, and 59.8 months among patients with relapses suspected clinically (P=.077). There was no significant difference in OS from date of first therapy or OS after relapse between patients whose relapse was suspected by imaging versus clinically. Thirteen of 18 patients underwent successful salvage therapy after relapse. CONCLUSIONS A complete response on PET scan immediately after initial chemotherapy is associated with superior FFP and OS in stage I to II DLBCL. The use of PET scans as posttreatment surveillance is not associated with a survival advantage. LDH is not a sensitive marker for relapse. Our results argue for limiting the use of posttreatment surveillance in patients with limited-stage DLBCL.
Collapse
|
29
|
|
30
|
Abel GA. Does Surveillance Imaging After Treatment for Diffuse Large B-Cell Lymphoma Really Work? J Clin Oncol 2015; 33:1427-9. [DOI: 10.1200/jco.2014.60.1120] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
El-Galaly TC, Hutchings M. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. Cancer Treat Res 2015; 165:125-46. [PMID: 25655608 DOI: 10.1007/978-3-319-13150-4_5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Optimal lymphoma management requires accurate pretreatment staging and reliable assessment of response, both during and after therapy. Positron emission tomography with computerized tomography (PET/CT) combines functional and anatomical imaging and provides the most sensitive and accurate methods for lymphoma imaging. New guidelines for lymphoma imaging and recently revised criteria for lymphoma staging and response assessment recommend PET/CT staging, treatment monitoring, and response evaluation in all FDG-avid lymphomas, while CT remains the method of choice for non-FDG-avid histologies. Since interim PET imaging has high prognostic value in lymphoma, a number of trials investigate PET-based, response-adapted therapy for non-Hodgkin lymphomas (NHL). PET response is the main determinant of response according to the new response criteria, but PET/CT has little or no role in routine surveillance imaging, the value which is itself questionable. This review presents from a clinical point of view the evidence for the use of imaging and primarily PET/CT in NHL before, during, and after therapy. The reader is given an overview of the current PET-based interventional NHL trials and an insight into possible future developments in the field, including new PET tracers.
Collapse
|
32
|
Moskowitz CH, Schöder H. Current Status of the Role of PET Imaging in Diffuse Large B-Cell Lymphoma. Semin Hematol 2015; 52:138-42. [DOI: 10.1053/j.seminhematol.2015.01.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
33
|
Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, Shovlin M, Jaffe ES, Staudt LM, Lai C, Steinberg SM, Chen CC, Zheng J, Willis TD, Faham M, Wilson WH. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 2015; 16:541-9. [PMID: 25842160 DOI: 10.1016/s1470-2045(15)70106-3] [Citation(s) in RCA: 310] [Impact Index Per Article: 34.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Diffuse large-B-cell lymphoma is curable, but when treatment fails, outcome is poor. Although imaging can help to identify patients at risk of treatment failure, they are often imprecise, and radiation exposure is a potential health risk. We aimed to assess whether circulating tumour DNA encoding the clonal immunoglobulin gene sequence could be detected in the serum of patients with diffuse large-B-cell lymphoma and used to predict clinical disease recurrence after frontline treatment. METHODS We used next-generation DNA sequencing to retrospectively analyse cell-free circulating tumour DNA in patients assigned to one of three treatment protocols between May 8, 1993, and June 6, 2013. Eligible patients had diffuse large-B-cell lymphoma, no evidence of indolent lymphoma, and were previously untreated. We obtained serial serum samples and concurrent CT scans at specified times during most treatment cycles and up to 5 years of follow-up. VDJ gene segments of the rearranged immunoglobulin receptor genes were amplified and sequenced from pretreatment specimens and serum circulating tumour DNA encoding the VDJ rearrangements was quantitated. FINDINGS Tumour clonotypes were identified in pretreatment specimens from 126 patients who were followed up for a median of 11 years (IQR 6·8-14·2). Interim monitoring of circulating tumour DNA at the end of two treatment cycles in 108 patients showed a 5-year time to progression of 41·7% (95% CI 22·2-60·1) in patients with detectable circulating tumour DNA and 80·2% (69·6-87·3) in those without detectable circulating tumour DNA (p<0·0001). Detectable interim circulating tumour DNA had a positive predictive value of 62·5% (95% CI 40·6-81·2) and a negative predictive value of 79·8% (69·6-87·8). Surveillance monitoring of circulating tumour DNA was done in 107 patients who achieved complete remission. A Cox proportional hazards model showed that the hazard ratio for clinical disease progression was 228 (95% CI 51-1022) for patients who developed detectable circulating tumour DNA during surveillance compared with patients with undetectable circulating tumour DNA (p<0·0001). Surveillance circulating tumour DNA had a positive predictive value of 88·2% (95% CI 63·6-98·5) and a negative predictive value of 97·8% (92·2-99·7) and identified risk of recurrence at a median of 3·5 months (range 0-200) before evidence of clinical disease. INTERPRETATION Surveillance circulating tumour DNA identifies patients at risk of recurrence before clinical evidence of disease in most patients and results in a reduced disease burden at relapse. Interim circulating tumour DNA is a promising biomarker to identify patients at high risk of treatment failure. FUNDING National Cancer Institute and Adaptive Biotechnologies.
Collapse
Affiliation(s)
- Mark Roschewski
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Kieron Dunleavy
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Stefania Pittaluga
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | | | | | | | - Margaret Shovlin
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Elaine S Jaffe
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Louis M Staudt
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Catherine Lai
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Seth M Steinberg
- Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Clara C Chen
- Nuclear Medicine Division, Clinical Center, National Institutes of Health, Bethesda, MD, USA
| | | | | | - Malek Faham
- Adaptive Biotechnologies, South San Francisco, CA, USA
| | - Wyndham H Wilson
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
| |
Collapse
|
34
|
Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol 2015; 33:1467-74. [PMID: 25823735 DOI: 10.1200/jco.2014.58.5729] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Surveillance imaging of asymptomatic patients with diffuse large B-cell lymphoma (DLBCL) in first remission remains controversial. A decision-analytic Markov model was developed to evaluate the cost-effectiveness of follow-up strategies following first-line immunochemotherapy. PATIENTS AND METHODS Three strategies were compared in 55-year-old patient cohorts: routine clinical follow-up without serial imaging, routine follow-up with biannual computed tomography (CT) scans for 2 years, or routine follow-up with biannual [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography (PET/CT) for 2 years. The baseline model favored imaging-based strategies by associating asymptomatic imaging-detected relapses with improved clinical outcomes. Lifetime costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated for each surveillance strategy. RESULTS Surveillance strategies utilizing 2 years of routine CT or PET/CT scans were associated with minimal survival benefit when compared with clinical follow-up without routine imaging (life-years gained: CT, 0.03 years; PET/CT, 0.04 years). The benefit of imaging-based follow-up remained small after quality-of-life adjustments (CT, 0.020 QALYs; PET/CT, 0.025 QALYs). Costs associated with imaging-based surveillance strategies are considerable; ICERs for imaging strategies compared with clinical follow-up were $164,960/QALY (95% CI, $116,510 to $766,930/QALY) and $168,750/QALY (95% CI, $117,440 to 853,550/QALY) for CT and PET/CT, respectively. Model conclusions were robust and remained stable on one-way and probabilistic sensitivity analyses. CONCLUSION Our cost-effectiveness analysis suggests surveillance imaging of asymptomatic DLBCL patients in remission offers little clinical benefit at substantial economic costs.
Collapse
Affiliation(s)
| | - Jakub Svoboda
- All authors: University of Pennsylvania, Philadelphia, PA
| | - Jalpa A Doshi
- All authors: University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
35
|
Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol 2015; 137:485-9. [PMID: 25838164 DOI: 10.1016/j.ygyno.2015.03.047] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2014] [Accepted: 03/20/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To evaluate surveillance methods and their utility in detecting recurrence of disease in a high grade endometrial cancer population. METHODS We performed a multi-institutional retrospective chart review of women diagnosed with high grade endometrial cancer between the years 2000 and 2011. Surveillance data was abstracted and analyzed. Surveillance method leading to detection of recurrence was identified and compared by stage of disease and site of recurrence. RESULTS Two hundred and fifty-four patients met the criteria for inclusion. Vaginal cytology was performed in the majority of early stage patients, but was utilized less in advanced stage patients. CA-125 and CT imaging were used more frequently in advanced stage patients compared to early stage. Thirty-six percent of patients experienced a recurrence and the majority of initial recurrences (76%) had a distant component. Modalities that detected cancer recurrences were: symptoms (56%), physical exam (18%), surveillance CT (15%), CA-125 (10%), and vaginal cytology (1%). All local recurrences were detected by symptoms or physical exam findings. While the majority of loco-regional and distant recurrences (68%) were detected by symptoms or physical exam, 28% were detected by surveillance CT scan or CA 125. One loco-regional recurrence was identified by vaginal cytology but no recurrences with a distant component detected by this modality. CONCLUSIONS Symptoms and physical examination identify the majority of high grade endometrial cancer recurrences, while vaginal cytology is the least likely surveillance modality to identify a recurrence. The role of CT and CA-125 surveillance outside of a clinical trial needs to be further reviewed.
Collapse
Affiliation(s)
- Jessica Hunn
- Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA
| | - Meaghan E Tenney
- Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA
| | - Ana I Tergas
- Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA
| | - Erin A Bishop
- University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Kathleen Moore
- University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - William Watkin
- Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA
| | - Carolyn Kirschner
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, USA
| | - Jean Hurteau
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, USA
| | - Gustavo C Rodriguez
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, USA
| | - Ernst Lengyel
- Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA
| | - Nita K Lee
- Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA
| | - S Diane Yamada
- Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
| |
Collapse
|
36
|
Chien SH, Liu CJ, Hu YW, Hong YC, Teng CJ, Yeh CM, Chiou TJ, Gau JP, Tzeng CH. Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study. Int J Cancer 2015; 137:658-65. [DOI: 10.1002/ijc.29433] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2014] [Accepted: 12/19/2014] [Indexed: 11/12/2022]
Affiliation(s)
- Sheng-Hsuan Chien
- Division of Hematology and Oncology, Department of Medicine; Taipei Veterans General Hospital; Taipei Taiwan
| | - Chia-Jen Liu
- Division of Hematology and Oncology, Department of Medicine; Taipei Veterans General Hospital; Taipei Taiwan
- School of Medicine; National Yang-Ming University; Taipei Taiwan
- Institute of Public Health, National Yang-Ming University; Taipei Taiwan
| | - Yu-Wen Hu
- School of Medicine; National Yang-Ming University; Taipei Taiwan
- Institute of Public Health, National Yang-Ming University; Taipei Taiwan
- Cancer Center, Taipei Veterans General Hospital; Taipei Taiwan
| | - Ying-Chung Hong
- School of Medicine; National Yang-Ming University; Taipei Taiwan
- Division of Hematology and Oncology, Department of Medicine; Kaohsiung Veterans General Hospital; Kaohsiung Taiwan
| | - Chung-Jen Teng
- School of Medicine; National Yang-Ming University; Taipei Taiwan
- Division of Oncology and Hematology, Department of Medicine; Far Eastern Memorial Hospital; Taipei Taiwan
| | - Chiu-Mei Yeh
- School of Medicine; National Yang-Ming University; Taipei Taiwan
| | - Tzeon-Jye Chiou
- School of Medicine; National Yang-Ming University; Taipei Taiwan
- Division of Transfusion Medicine, Department of Medicine; Taipei Veterans General Hospital; Taipei Taiwan
| | - Jyh-Pyng Gau
- Division of Hematology and Oncology, Department of Medicine; Taipei Veterans General Hospital; Taipei Taiwan
- School of Medicine; National Yang-Ming University; Taipei Taiwan
| | - Cheng-Hwai Tzeng
- Division of Hematology and Oncology, Department of Medicine; Taipei Veterans General Hospital; Taipei Taiwan
- School of Medicine; National Yang-Ming University; Taipei Taiwan
| |
Collapse
|
37
|
Abstract
The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.
Collapse
|
38
|
Cohen JB, Flowers CR. Optimal disease surveillance strategies in non-Hodgkin lymphoma. HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM 2014; 2014:481-487. [PMID: 25696898 DOI: 10.1182/asheducation-2014.1.481] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Given the paucity of randomized controlled trial data, defining the ideal strategy for surveillance imaging in patients with non-Hodgkin lymphoma (NHL) has become increasingly challenging. The routine use of frequent surveillance scans has been a common component of patient care. Emerging data from prospective and retrospective observational studies and modeling approaches have highlighted the performance characteristics of imaging modalities and the challenges with this form of secondary screening. The majority of patients with relapsed lymphoma have clinical signs or symptoms that prompt further evaluation, and only a small proportion of patients experience relapse detected on a routine scan while being otherwise asymptomatic. Surveillance imaging is costly, may expose patients to minimal risks of mortality due to radiation-related secondary malignancies, and can lead to false-positive findings, leading to unnecessary biopsies. In addition, no prospective study has demonstrated a significant improvement in overall survival for those patients whose disease is discovered on a routine scan versus those who present with clinical symptoms. In this chapter, we examine the baseline risks of relapse for various NHL subtypes that provide the context for surveillance, review the data on imaging modalities, and establish a framework for discussing optimal surveillance strategies with individual patients. Patients should be counseled on the risks and benefits of routine surveillance imaging and decisions regarding surveillance should be made on an individual basis using patient-specific risk factors, response to induction therapy, and patient preferences with a bias toward using surveillance imaging in the 2 years after treatment only in those NHL patients with the greatest likelihood of benefit.
Collapse
|
39
|
Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, Chassagne-Clément C, Inwards DJ, Gargi T, Johnston PB, Nicolas-Virelizier E, Macon WR, Peix M, Micallef IN, Sebban C, Nowakowski GS, Porrata LF, Weiner GJ, Witzig TE, Habermann TM, Link BK. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol 2014; 32:3506-12. [PMID: 25267745 DOI: 10.1200/jco.2014.55.7561] [Citation(s) in RCA: 132] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
PURPOSE We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France. METHODS Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records. RESULTS 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P = .56) and Lyon cohorts (P = .25). CONCLUSION The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.
Collapse
Affiliation(s)
- Carrie A Thompson
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA.
| | - Herve Ghesquieres
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Matthew J Maurer
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - James R Cerhan
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Pierre Biron
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Stephen M Ansell
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Catherine Chassagne-Clément
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - David J Inwards
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Thérèse Gargi
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Patrick B Johnston
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Emmanuelle Nicolas-Virelizier
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - William R Macon
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Marie Peix
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Ivana N Micallef
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Catherine Sebban
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Grzegorz S Nowakowski
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Luis F Porrata
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - George J Weiner
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Thomas E Witzig
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Thomas M Habermann
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| | - Brian K Link
- Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA
| |
Collapse
|
40
|
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059-68. [PMID: 25113753 PMCID: PMC4979083 DOI: 10.1200/jco.2013.54.8800] [Citation(s) in RCA: 3421] [Impact Index Per Article: 342.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A workshop was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists, radiologists, and nuclear medicine physicians, representing major international lymphoma clinical trials groups and cancer centers. Clinical and imaging subcommittees presented their conclusions at a subsequent workshop at the 12th International Conference on Malignant Lymphoma, leading to revised criteria for staging and of the International Working Group Guidelines of 2007 for response. As a result, fluorodeoxyglucose (FDG) positron emission tomography (PET)–computed tomography (CT) was formally incorporated into standard staging for FDG-avid lymphomas. A modification of the Ann Arbor descriptive terminology will be used for anatomic distribution of disease extent, but the suffixes A or B for symptoms will only be included for HL. A bone marrow biopsy is no longer indicated for the routine staging of HL and most diffuse large B-cell lymphomas. However, regardless of stage, general practice is to treat patients based on limited (stages I and II, nonbulky) or advanced (stage III or IV) disease, with stage II bulky disease considered as limited or advanced disease based on histology and a number of prognostic factors. PET-CT will be used to assess response in FDG-avid histologies using the 5-point scale. The product of the perpendicular diameters of a single node can be used to identify progressive disease. Routine surveillance scans are discouraged. These recommendations should improve evaluation of patients with lymphoma and enhance the ability to compare outcomes of clinical trials.
Collapse
Affiliation(s)
- Bruce D. Cheson
- Bruce D. Cheson, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA; Sally F. Barrington, St Thomas' Hospital; T. Andrew Lister, St Bartholomew's Hospital, London, United Kingdom; Franco Cavalli and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and Lawrence H. Schwartz, Columbia University, New York, NY
- Corresponding author: Bruce D. Cheson, MD, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007; e-mail:
| | - Richard I. Fisher
- Bruce D. Cheson, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA; Sally F. Barrington, St Thomas' Hospital; T. Andrew Lister, St Bartholomew's Hospital, London, United Kingdom; Franco Cavalli and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and Lawrence H. Schwartz, Columbia University, New York, NY
| | - Sally F. Barrington
- Bruce D. Cheson, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA; Sally F. Barrington, St Thomas' Hospital; T. Andrew Lister, St Bartholomew's Hospital, London, United Kingdom; Franco Cavalli and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and Lawrence H. Schwartz, Columbia University, New York, NY
| | - Franco Cavalli
- Bruce D. Cheson, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA; Sally F. Barrington, St Thomas' Hospital; T. Andrew Lister, St Bartholomew's Hospital, London, United Kingdom; Franco Cavalli and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and Lawrence H. Schwartz, Columbia University, New York, NY
| | - Lawrence H. Schwartz
- Bruce D. Cheson, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA; Sally F. Barrington, St Thomas' Hospital; T. Andrew Lister, St Bartholomew's Hospital, London, United Kingdom; Franco Cavalli and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and Lawrence H. Schwartz, Columbia University, New York, NY
| | - Emanuele Zucca
- Bruce D. Cheson, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA; Sally F. Barrington, St Thomas' Hospital; T. Andrew Lister, St Bartholomew's Hospital, London, United Kingdom; Franco Cavalli and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and Lawrence H. Schwartz, Columbia University, New York, NY
| | - T. Andrew Lister
- Bruce D. Cheson, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA; Sally F. Barrington, St Thomas' Hospital; T. Andrew Lister, St Bartholomew's Hospital, London, United Kingdom; Franco Cavalli and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and Lawrence H. Schwartz, Columbia University, New York, NY
| |
Collapse
|
41
|
Lukenbill J, Hill B. Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients. Leuk Lymphoma 2014; 56:293-300. [DOI: 10.3109/10428194.2014.910660] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
42
|
El-Galaly TC, Mylam KJ, Bøgsted M, Brown P, Rossing M, Gang AO, Haglund A, Arboe B, Clausen MR, Jensen P, Pedersen M, Bukh A, Jensen BA, Poulsen CB, d'Amore F, Hutchings M. Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol 2014; 89:575-80. [PMID: 24493389 DOI: 10.1002/ajh.23688] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Accepted: 01/29/2014] [Indexed: 11/10/2022]
Abstract
After first-line therapy, patients with Hodgkin lymphoma (HL) and aggressive non-HL are followed up closely for early signs of relapse. The current follow-up practice with frequent use of surveillance imaging is highly controversial and warrants a critical evaluation. Therefore, a retrospective multicenter study of relapsed HL and aggressive non-HL (nodal T-cell and diffuse large B-cell lymphomas) was conducted. All included patients had been diagnosed during the period 2002-2011 and relapsed after achieving complete remission on first-line therapy. Characteristics and outcome of imaging-detected relapses were compared with other relapses. A total of 258 patients with recurrent lymphoma were included in the study. Relapse investigations were initiated outside preplanned visits in 52% of the patients. Relapse detection could be attributed to patient-reported symptoms alone or in combination with abnormal blood tests or physical examination in 64% of the patients. Routine imaging prompted relapse investigations in 27% of the patients. The estimated number of routine scans per relapse was 91-255 depending on the lymphoma subtype. Patients with imaging-detected relapse had lower disease burden (P = 0.045) and reduced risk of death following relapse (hazard ratio = 0.62, P = 0.02 in multivariate analysis). Patient-reported symptoms are still the most common factor for detecting lymphoma relapse and the high number of scans per relapse calls for improved criteria for use of surveillance imaging. However, imaging-detected relapse was associated with lower disease burden and a possible survival advantage. The future role of routine surveillance imaging should be defined in a randomized trial.
Collapse
Affiliation(s)
- TC El-Galaly
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
- Department of Hematology; Aarhus University Hospital; Aarhus Denmark
| | - Karen Juul Mylam
- Department of Hematology; Odense University Hospital; Odense Denmark
| | - Martin Bøgsted
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
- Department of Mathematical Sciences; Aalborg University; Aalborg Denmark
| | - Peter Brown
- Department of Hematology; Rigshospitalet; Copenhagen University Hospital; Copenhagen Denmark
| | - Maria Rossing
- Department of Hematology; Rigshospitalet; Copenhagen University Hospital; Copenhagen Denmark
| | - Anne Ortved Gang
- Department of Hematology; Herlev; Copenhagen University Hospital; Herlev Denmark
| | - Anne Haglund
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| | - Bente Arboe
- Department of Hematology; Roskilde Hospital; Roskilde Denmark
| | | | - Paw Jensen
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| | - Michael Pedersen
- Department of Hematology; Herlev; Copenhagen University Hospital; Herlev Denmark
| | - Anne Bukh
- Department of Hematology; Aarhus University Hospital; Aarhus Denmark
| | - Bo Amdi Jensen
- Department of Hematology; Odense University Hospital; Odense Denmark
| | | | - Francesco d'Amore
- Department of Hematology; Aarhus University Hospital; Aarhus Denmark
| | - Martin Hutchings
- Department of Hematology; Rigshospitalet; Copenhagen University Hospital; Copenhagen Denmark
| |
Collapse
|
43
|
|
44
|
Hong J, Kim JH, Lee KH, Ahn HK, Park S, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55:2312-8. [PMID: 24428199 DOI: 10.3109/10428194.2014.882505] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
This study aimed at evaluating the role of routine imaging versus symptom-directed unplanned early outpatient department (OPD) visits in patients with diffuse large B-cell lymphoma (DLBCL) in complete remission (CR) by analyzing the patterns and outcomes of OPD visits for disease monitoring. Patients with DLBCL in CR after treatment in the rituximab era with any OPD monitoring visit were analyzed. A total of 856 OPD visits were recorded: 501 visits were with routine imaging, 322 were without routine imaging and 33 visits (3.9%) were unplanned early visits due to abnormal symptoms. Of the 106 analyzed patients, 15 experienced a relapse (median follow-up duration of 38.1 months). Routine imaging showed an unsatisfactory positive predictive value due to frequent false-positive visits, and a substantial number of patients with false-positive imaging underwent unnecessary biopsies or additional scans. Compared with planned OPD visits, unplanned early visits were highly related to relapse.
Collapse
Affiliation(s)
- Junshik Hong
- Department of Internal Medicine, Gachon University Gil Hospital, Gachon University School of Medicine , Incheon , Republic of Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Cheah CY, Dickinson M, Hofman MS, George A, Ritchie DS, Prince HM, Westerman D, Harrison SJ, Burbury K, Wolf M, Januszewicz H, Herbert KE, Carney DA, Tam C, Seymour JF. Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. Ann Hematol 2014; 93:1193-200. [PMID: 24595733 DOI: 10.1007/s00277-014-2040-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2014] [Accepted: 02/15/2014] [Indexed: 11/26/2022]
Abstract
The optimum follow-up of patients with transformed indolent lymphoma (TrIL) is not well defined. We sought to determine the utility of surveillance positron emission tomography-computed tomography (PET-CT) in patients with TrIL achieving complete metabolic remission (CMR) after primary therapy. We performed a retrospective analysis of patients with TrIL treated at Peter MacCallum Cancer Centre between 2002 and 2012 who achieved CMR after primary therapy who had ≥1 subsequent surveillance PET-CT. Of 55 patients with TrIL, 37 (67 %) received autologous stem cell transplantation as consolidation following chemoimmunotherapy. After a median follow-up of 34 (range 3-101) months, the actuarial 3-year progression-free (PFS) and overall survival (OS) were 77 % (95 %CI 62-86 %) and 88 % (75-94 %), respectively. Of 180 surveillance PET-CT scans, there were 153 true negatives, 4 false positives, 1 false negative, 7 indeterminate and 15 true positives. Considering indeterminate scans as false positives, the specificity of PET-CT for detecting relapse was 94 %, sensitivity was 83 %, positive predictive value was 63 % and negative predictive value was 98 %. All seven subclinical (PET detected) relapses were of low-grade histology; in contrast, all nine relapses with diffuse large B cell lymphoma (DLBCL) were symptomatic. In our cohort of patients with TrIL achieving CMR, PET-CT detected subclinical low-grade relapses but all DLBCL relapses were accompanied by clinical symptoms. Thus, surveillance imaging of patients with TrIL achieving CMR is of limited clinical benefit. PET-CT should be reserved for evaluation of clinically suspected relapse.
Collapse
Affiliation(s)
- Chan Y Cheah
- Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, East Melbourne, 8006, Victoria, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, Hamadani M. Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2014; 14:50-5. [DOI: 10.1016/j.clml.2013.08.009] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Revised: 08/29/2013] [Accepted: 08/29/2013] [Indexed: 12/20/2022]
|
47
|
Cheah CY, Seymour JF. Adding weight to a sinking ship: more reasons not to perform routine surveillance imaging in patients with diffuse large B-cell lymphoma in remission. Leuk Lymphoma 2014; 55:2223-5. [PMID: 24410590 DOI: 10.3109/10428194.2014.881483] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Chan Y Cheah
- Department of Haematology, Peter MacCallum Cancer Centre , East Melbourne, Victoria , Australia and University of Melbourne , Parkville, Victoria , Australia
| | | |
Collapse
|
48
|
Lynch RC, Zelenetz AD, Armitage JO, Carson KR. Surveillance imaging for lymphoma: pros and cons. Am Soc Clin Oncol Educ Book 2014:e388-e395. [PMID: 24857129 DOI: 10.14694/edbook_am.2014.34.e388] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
There is no international consensus on the optimal frequency or duration of computed tomography or positron emission tomography scanning for surveillance in patients who achieve complete remission after initial therapy for lymphoma. Although some clinical practice guidelines suggest periodic imaging is reasonable, others suggest little or no benefit to this practice. From a theoretical perspective, the frequency and duration of surveillance imaging is largely dependent upon the lymphoma subtype. Aggressive lymphomas with a fast growth rate will require surveillance more frequently and for a shorter duration compared to the indolent lymphomas. Historically, relapse has been detected in a majority of patients based upon clinically evident signs and symptoms. Currently, no study has demonstrated an overall survival difference for patients with relapse detected by imaging as opposed to clinical evaluation, although one study did demonstrate a lower second-line International Prognostic Index in patients with relapse detected by surveillance imaging. Enthusiasm for this finding has been tempered by recent studies highlighting the potential long-term risk of secondary malignancies because of ionizing radiation exposure from diagnostic imaging. These factors along with the significant costs associated with diagnostic imaging have contributed to an ongoing debate regarding the relative costs, risks, and benefits of radiographic surveillance. Herein we present perspectives for and against routine surveillance imaging in an effort to facilitate a better understanding of the issues relevant to what is ultimately a clinical decision made by an oncologist and his or her patient.
Collapse
Affiliation(s)
- Ryan C Lynch
- From the: Division of Hospital Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO; Lymphoma Division, Memorial Sloan Kettering Cancer Center, New York, NY; Division of Oncology, Department of Medicine, University of Nebraska; Division of Oncology, Department of Medicine, Washington University School of Medicine; and Division of Hematology/Oncology, St. Louis VA Medical Center, St. Louis, MO
| | - Andrew D Zelenetz
- From the: Division of Hospital Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO; Lymphoma Division, Memorial Sloan Kettering Cancer Center, New York, NY; Division of Oncology, Department of Medicine, University of Nebraska; Division of Oncology, Department of Medicine, Washington University School of Medicine; and Division of Hematology/Oncology, St. Louis VA Medical Center, St. Louis, MO
| | - James O Armitage
- From the: Division of Hospital Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO; Lymphoma Division, Memorial Sloan Kettering Cancer Center, New York, NY; Division of Oncology, Department of Medicine, University of Nebraska; Division of Oncology, Department of Medicine, Washington University School of Medicine; and Division of Hematology/Oncology, St. Louis VA Medical Center, St. Louis, MO
| | - Kenneth R Carson
- From the: Division of Hospital Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO; Lymphoma Division, Memorial Sloan Kettering Cancer Center, New York, NY; Division of Oncology, Department of Medicine, University of Nebraska; Division of Oncology, Department of Medicine, Washington University School of Medicine; and Division of Hematology/Oncology, St. Louis VA Medical Center, St. Louis, MO
| |
Collapse
|
49
|
Abstract
Abstract
Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curative-intent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.
Collapse
|
50
|
Abstract
Abstract
Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curative-intent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.
Collapse
|